ENU (N-ethyl-N-nitrosourea) is a chemical mutagen that randomly induces point mutations in DNA. Since the 1990s ENU has been successfully used as a means to obtain mouse mutants using both gene-driven (reverse genetics) and phenotype-driven (forward genetics) approaches. A high-efficiency ENU approach results in approx. 25 functional mutations per genome; most of these will result in hypomorphic alleles. Our group has recently begun using ENU mutagenesis as a tool for understanding lung development and disease. In collaboration with other groups at MRC Harwell, we have undertaken a screen for recessive mutations affecting mouse lung development. We are currently pursuing two lines identified from this screen, Hel (head, eye and lung) and RecBA17. Both these lines exhibit lung defects and we believe that by studying the phenotypes and identifying the causative mutations, we may also shed light on lung disease pathogenesis. In collaboration with Bill Cookson and Miriam Moffatt, we are also taking a gene-driven approach for understanding asthma. Using the Harwell ENU sperm archive, we have recovered mouse lines harbouring mutations in the asthma-susceptibility genes Phf11 (PHD finger protein 11) and Dpp10 (dipeptidylpeptidase 10). Functional analyses of these alleles are currently under way.
Using ENU (N-ethyl-N-nitrosourea) to induce mutations in mice
The mouse has become one of the preferred organisms for studies of human disease. Mice are easy to breed, they have a relatively short generation time and a number of techniques are available to manipulate murine genes including: knockin and knockout strategies and creation of conditional alleles. In addition, the mouse genome has been sequenced and, importantly, many human disease states appear to be mirrored in mice after genetic manipulation.
ENU is now the mutagen of choice for the random induction of mutations in mice and, along with gene-targeting approaches, this chemical is a powerful tool for studies of disease biology. After administration of ENU through intraperitoneal injection to adult male mice, mutations are induced by transfer of an ethyl group to any of a number of sites on each of the four deoxyribonucleotides [1] . The dosage and number of injections of ENU are critical as too much will affect both the viability and long-term fertility of the mice [2, 3] , whereas too little allows repair of mutations by normal cellular DNA repair mechanisms [4, 5] . One of the major sites for ENU action in the mouse is spermatogonial stem cells, thus enabling mutations to be transmitted to the next generation [6, 7] .
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In most of the cases, ENU induces point mutations, although occasionally small deletions can also occur. Between 70 and 85 % of point mutations will occur at A-T base pairs and G-C-to-C-G transitions are rarely seen. An effective ENU dosage will result in one mutation every 1-1.5 Mb and therefore larger genes have a higher chance of being mutated [8] [9] [10] [11] . Despite these caveats, ENU mutagenesis has proved to be an extremely successful method for understanding gene function [12, 13] .
Phenotype-driven approaches
Forward genetics (phenotype to gene) has been widely used to identify mouse models of disease as well as genes involved in the development of particular organs or processes [12, 14, 15] . A major advantage of this approach is that it is completely unbiased and does not make any assumptions about the genetic basis of a disease or developmental process. Screens for both dominant and recessive mutations can be conducted and are usually limited only by the complexity and necessary timescale of the particular phenotyping assay employed to identify phenodeviants. More recently, phenotyping pipelines have been used where individuals are screened for a number of different phenotypes, thus maximizing the data obtained from a single mouse.
Over the last year, our laboratory has been focusing on two mouse mutants with particularly interesting lung phenotypes. Both these lines: Hel (head, eye and lung) and RecBA17 were identified in an ongoing screen for recessive mutations affecting development [16] . In this screen, C57BL/6 males are treated with ENU and, after a period of sterility, the males are mated with C3H females. Half of the resulting G 1 mice are heterozygous for the ENU-induced mutations. G 1 male mice are then crossed to wild-type C3H females to obtain G 3 offspring, which can then be either intercrossed or mated back to the G 1 founder male to homozygose the mutations. The G 3 mice are screened for the phenotype of interest and the mutation is mapped using polymorphisms between the mutagenized strain (C57BL/6) and the wildtype strain used for crosses (C3H). Although each G 1 mouse contains an average of 25 functional mutations, it has been found that in most cases the mutant phenotype is the result of a coding mutation in a single gene [17] . Since many of the genes required for lung development also appear to be involved in disease, we expect that these studies will increase our understanding of both lung development and disease. Although a large number of ENU-induced mutations result in embryonic lethality, in the case of recessive mutations, heterozygotes are often viable and can be used for postnatal studies of lung disease.
Hel
In addition to lung defects, Hel homozygotes exhibit exencephaly and eye defects such as ocular coloboma (Figure 1) . The lungs are hypoplastic and, to date, no phenotypic homozygous mice have been observed postnatally, indicating that they die around birth. An SNP (single nucleotide polymorphism)-based genome scan localized the mutation to a region on chromosome 10, which we have since refined to between 24 and 28 Mb. We are currently sequencing a number of candidate genes within this region.
At E13.5 (embryonic day 13.5), Hel/Hel lungs are smaller than those of wild-type littermates and have fewer epithelial branches, suggesting that development is delayed. H/E (haematoxylin/eosin) sections of lung did not reveal any gross abnormalities of the tissue but did confirm that fewer branches were present in homozygotes. In addition, a comparison of the percentage of proliferating cells and those undergoing apoptosis at E13.5 showed decreased proliferation and an increase in apoptosis in Hel homozygous lungs compared with wild-type littermates. Most strikingly, we observed a severe decrease in PECAM (platelet/endothelial cell adhesion molecule) staining throughout mutant lungs, suggesting that blood vessel formation is affected ( Figure 2) ; indeed in some later stage lungs we observed pooling of blood around the edges of the lobes suggesting that the blood vessels may be leaky.
By E18.5, Hel/Hel lungs are much more severely affected. H/E staining revealed severe defects in sacculation in Hel homozygous lungs. This kind of defect is highly likely to severely affect breathing and cause the perinatal lethality that we have observed in this line. Immunohistochemical examination of the lung cell-type-specific markers: Clara cell 10 and aquaporin 5 did not reveal any differences between wild-type and mutant littermates. Interestingly, staining with an antibody against smooth-muscle actin revealed Our data showing defects in proliferation and apoptosis at E13.5 indicate that the mutation in Hel leads to lung defects early in development and these worsen progressively over time. Future studies with this line will include identification of the causative mutation and further phenotypic characterization, particularly to understand the smoothmuscle and blood vessel defects. We will determine whether Hel mice or others carrying mutations in the same gene may be useful models for studies of lung diseases, particularly where the vasculature and/or smooth muscle is affected such as bronchopulmonary dysplasia or asthma.
RecBA17
We are just beginning our characterization of RecBA17, which was also isolated from the same screen at MRC Harwell. The morphological phenotype [18, 19] includes fused lung lobes with delayed branching morphogenesis. The lungs also appear shorter than wild-type littermates; this is particularly noticeable in the right lobes (Figure 3) . Interestingly, the tails of these mice are also shortened, suggesting that the underlying mutation may be affecting one or more of the Hox genes whose function is to determine the length of the rostral-caudal axis of the embryo itself and of structures within the embryo. 
Gene-driven approaches
Over the last few years, a number of human asthmasusceptibility genes have been identified including ADAM33 (a disintegrin and metalloproteinase 33) [20] , DPP10 (dipeptidylpeptidase 10) [21] , PHF11 (PHD finger protein 11) [22] and ORMDL3 (ORM1-like 3) [23] . A major challenge for the future is to understand the function of these and other lung disease genes in order to shed light on disease pathogenesis and for this we require model systems. ENU mutagenesis can be used as an alternative approach to traditional gene targeting methods, such as knockouts, in order to generate mouse models and understand gene function. Indeed ENU mutagenesis has already shed light on a number of human diseases including diabetes [24] and otitis media [25, 26] .
In this reverse genetics approach (gene to phenotype), DNA archives are screened for mutations in a gene of interest [8] . DNA may be obtained from either parallel archives of DNA and frozen sperm obtained from G 1 progenies of mutagenized males [11] or from mutagenized ES cells [10, 27] . The increasing number of DNA samples in these archives means that they are likely to contain at least one mutation in any given gene of interest. Mutation detection can be carried out using techniques such as TGCE (temperature gradient capillary electrophoresis), DHPLC (denaturing HPLC) and direct sequencing [11] . In many cases, it is possible to recover an allelic series of point mutations within a single gene that can shed light on critical functional domains and may be extremely useful for identifying druggable targets. Once identified, mice carrying the ENU mutation of interest can be generated, from either sperm or ES cells depending on which archive was screened.
Dpp10 and Phf11
Using a gene-driven approach, we screened the Harwell ENU archive for mutations in the asthma-susceptibility genes Dpp10 and Phf11. Mouse lines harbouring mutations in both these genes were subsequently re-derived from frozen sperm and backcrossed to ensure that each line contains only our mutation of interest. Both Dpp10 and Phf11 homozygotes are viable and lung histology appears normal. Further assessment of these mice is under way including specific lung phenotyping assays such as plethysmography and assessment of susceptibility to asthma. ENU mutagenesis is a powerful tool for the study of gene function. Among the various benefits of this approach are the potential to create a variety of different mutations including loss-of-function, hypomorphs and dominant-negative mutations. Furthermore, using ENU archives, it is possible to recover additional alleles of a gene of interest that can provide important information about the function of the gene. In the future it is likely that ENU mutagenesis will provide useful models for the study of lung disease.
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